We provide you with 20 years of free, institutional-grade data for AVTE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVTE. Explore the full financial landscape of AVTE stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-13 | 1798749 | AVTE | 10-Q | Url |
| 2025-04-25 | 1798749 | AVTE | 10-Q | Url |
| 2025-03-27 | 1798749 | AVTE | 10-K | Url |
| 2024-11-12 | 1798749 | AVTE | 10-Q | Url |
| 2024-08-12 | 1798749 | AVTE | 10-Q | Url |
| 2024-05-13 | 1798749 | AVTE | 10-Q | Url |
| 2024-03-25 | 1798749 | AVTE | 10-K | Url |
| 2023-11-13 | 1798749 | AVTE | 10-Q | Url |
| 2023-08-14 | 1798749 | AVTE | 10-Q | Url |
| 2023-05-15 | 1798749 | AVTE | 10-Q | Url |
| 2023-03-29 | 1798749 | AVTE | 10-K | Url |
| 2022-11-14 | 1798749 | AVTE | 10-Q | Url |
| 2022-08-15 | 1798749 | AVTE | 10-Q | Url |
| 2022-05-16 | 1798749 | AVTE | 10-Q | Url |
| 2022-03-30 | 1798749 | AVTE | 10-K | Url |
| 2021-11-15 | 1798749 | AVTE | 10-Q | Url |
| 2021-08-16 | 1798749 | AVTE | 10-Q | Url |
| 2021-06-09 | 1798749 | AVTE | S-1 | Url |
Aerovate Therapeutics Inc(NASDAQ:AVTE) 
Aerovate Therapeutics is a clinical stage biopharmaceutical company whose mission is to advance novel therapeutics and to help people with rare cardiopulmonary diseases gain control over their health, and their lives.
Website: https://www.aerovatetx.com/
Founded: 2018
IPO Price: $14 (Jun 29, 2021)
CEO: Tim Noyes
Sector:
Industry:
The information provided in this report about AVTE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.